| abstract |
The present invention relates to the use of a compound of general formula (I) or (II) wherein R1 is H, lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkyl or CF3; R2 and R3 are independently H, lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkyl, (a), with the proviso that one of R2 or R3 is (b) wherein W is O, S, NH or N-lower alkyl; R4 is H, lower alkyl or lower acyl; R5 is H, lower alkyl, aryl-lower alkyl, cyclopropyl or lower perfluoroalkyl; Ar is phenyl, furyl, thienyl, naphthyl, pyridyl or pyrrolyl, optionally substituted by R6; R6 is one or more groups selected from lower alkyl, lower acyl, halogen, lower alkoxy, CF3, OH, NO2 or NR7R8, wherein R7 and R8 independently are H, lower alkyl or lower acyl; R9 is CH2-halogen, CH3 or COOH; R10 is H, OH or =O; R11 is H or OH; geometrical and optical isomers, tautomers and racemates thereof where such isomers or tautomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof, for the preparation of a medicament for the treatment and/or prevention of p38 MAP kinase mediated disorders. |